F Dx Advisors, Inc. Hutchmed (China) LTD Transaction History

F Dx Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$8.59 - $20.77 $87,592 - $211,791	-10,197 Closed	0 $0
Q1 2022 May 03, 2022	SELL	$15.52 - $35.65 $3,197 - $7,343	-206 Reduced 1.98%	10,197 $193,000
Q4 2021 Feb 01, 2022	SELL	$28.89 - $35.33 $18,865 - $23,070	-653 Reduced 5.91%	10,403 $365,000
Q3 2021 Oct 08, 2021	SELL	$35.66 - $42.94 $4,029 - $4,852	-113 Reduced 1.01%	11,056 $405,000
Q2 2021 Aug 05, 2021	SELL	$23.7 - $39.27 $5,261 - $8,717	-222 Reduced 1.95%	11,169 $439,000
Q1 2021 Apr 14, 2021	BUY	$27.01 - $36.8 $298,973 - $407,339	11,069 Added 3437.58%	11,391 $322,000
Q1 2021 Apr 13, 2021	SELL	$27.01 - $36.8 $292,815 - $398,948	-10,841 Reduced 97.12%	322 $9,000
Q4 2020 Feb 08, 2021	BUY	$27.51 - $34.36 $3,026 - $3,779	110 Added 1.0%	11,163 $357,000
Q3 2020 Nov 12, 2020	BUY	$25.8 - $34.61 $285,167 - $382,544	11,053 New	11,053 $357,000

6.76M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.29B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.